Insider Buying: Amicus Therapeutics, Inc. (NASDAQ:FOLD) Director Acquires $49,796.15 in Stock
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Director Burke W. Whitman purchased 4,945 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, August 23rd. The shares were acquired at an average price of $10.07 per share, for a total transaction of $49,796.15. Following the acquisition, the director now owns 21,612 shares in the company, valued at $217,632.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
FOLD stock opened at $10.24 on Friday. Amicus Therapeutics, Inc. has a fifty-two week low of $8.27 and a fifty-two week high of $14.61. The business’s 50 day moving average price is $11.50 and its two-hundred day moving average price is $12.38. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.97 and a current ratio of 7.09. The company has a market capitalization of $2.49 billion, a price-to-earnings ratio of -7.70 and a beta of 1.85.
Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.34). Amicus Therapeutics had a negative return on equity of 66.79% and a negative net margin of 336.41%. The firm had revenue of $44.13 million for the quarter, compared to the consensus estimate of $41.14 million. During the same quarter in the prior year, the business earned ($0.33) EPS. The business’s revenue for the quarter was up 107.1% on a year-over-year basis. Sell-side analysts forecast that Amicus Therapeutics, Inc. will post -1.3 earnings per share for the current year.
A number of research analysts recently issued reports on the company. Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. BidaskClub downgraded Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 15th. ValuEngine downgraded Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Amicus Therapeutics in a report on Thursday, August 1st. Finally, Cowen restated a “buy” rating and set a $31.00 price target on shares of Amicus Therapeutics in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $18.06.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Featured Story: Why do commodities matter?
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.